Compare Regeneron Pharmaceuticals Inc (REGN) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Unum Group Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $787.79 (market cap $77.54B), while Unum Group Common Stock trades at $91.42 (market cap $14.57B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.3× Unum Group Common Stock's market cap, and Unum Group Common Stock pays the higher dividend (2.19%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Unum Group Common Stock for 0 Days on average.
| REGN | UNM | |
|---|---|---|
Market Cap | $77.54B | $14.57B |
Volume | 629,519 | 1,461,588 |
Sector | Health | Financials |
52-Week High | $852.03 | $96.57 |
52-Week Low | $569.17 | $70.66 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $72.25B | $18.14B |
Dividend Yield | 0.5% | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $778.36, up 2.04% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant expansion of its immunology alliance with Sanofi, valued up to $8 billion, which could drive future growth. Valuation ratios appear reasonable, with a P/E of 18.64 and robust profitability margins.
The outlook for REGN is positive, supported by strong earnings momentum, a lucrative partnership expansion, and a unanimous analyst buy consensus. Key risks include competitive pressures in the biopharma space and reliance on key drug performance. The stock presents a compelling opportunity for growth investors, with a consensus price target of $849.84 suggesting upside potential.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
